Michael Fernando and Josh Hurwitz

Oncology for the Inquisitive Mind

Health EN ↓ 239 episodes

Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.

Be sure to visit the podcast's website and support the creator: www.inquisitiveonc.com

Author

Michael Fernando and Josh Hurwitz

Category

Health

Podcast website

www.inquisitiveonc.com

Latest episode

Nov 17, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS 09.04.2026

UPDATED WITH CORRECT AUDIO While Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF mutations in colorectal cancer were historically prognostic; this has now shifted with targeted therapies available for both. In the context of metastatic colorectal cancer, BRAF muta...

195. Back to Basics - Immunotherapy in Metastatic Colorectal Cancer 28.03.2026

Historically, colorectal cancer treatment has been fairly standard, but this has shifted over the past decade with the introduction of targeted therapies. This week, our focus is on patients with microsatellite instability (dMMR) colorectal cancer, a small but meaningful cohort. This condition affects up to 15% of patients, many of whom carry germline mutations in the MLH1 and MSH2 genes, which si...

194. Back to Basics - Metastatic Colorectal Cancer 21.03.2026

Metastatic colorectal cancer is one of the leading causes of cancer-related deaths and among the most common types of cancer worldwide. Chemotherapy remains the main treatment, but the question is: how can we make it more effective without increasing toxicity?   This week, we explore the intensification of chemotherapy in an effort to improve overall survival. The second topic involves the us...

193. Genitourinary Cancers and Prof Jonathan E Rosenberg MD 14.03.2026

Professor Jonathan E. Rosenberg, MD, serves as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Centre (MSKCC). He is a prolific researcher and author, holding multiple titles including Attending Physician at MSKCC, Professor of Medicine at Weill Cornell Medical College, and the Enno W. Ercklentz Chair in Genitourinary Oncology. Today, Jonathan explores metastatic...

192. Back to Basics - Early Colorectal Cancer - Part 2! 07.03.2026

The DYNAMIC duo are back, with Michael climbing the "Everest" of oncology and exploring the role of CTDNA in stage two colorectal cancer. Josh has the easier job of exploring neoadjuvant immunotherapy (ipilimumab and nivolumab) in dMMR advanced colorectal cancer. Both are excellent trials, and a worthy addition to your reading list. Don't forget to check us out on YouTube if that's your thing! Stu...

191. Back to Basics - Early Colorectal Cancer 28.02.2026

This week, we explore early colorectal cancer. Maybe it’s just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or CAPOX. Josh digs a bit deeper and, as the name suggests, looks at whether patients with liver metastases can be cured with chemotherapy and a liver transplant. Studies discussed in...

190. Back to Basics - Mesothelioma 21.02.2026

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published...

189. Back to Basics - Extensive Stage Small Cell Lung Cancer 16.02.2026

This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a faster rate than in the last twenty years combined. We explore tarlatamab, a bispecific delta-like ligand 3-directed T cell engager. The results show that, in the second-line settin...

188. Gastrointestinal Cancer and Professor Jenny Seligmann 11.02.2026

Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, is renowned for leading the groundbreaking FOxTROT and ARIEL trials. These studies challenged traditional practices by demonstrating the advantages of administering chemotherapy&nbs...

187. ESMO Awards - Episode 7 02.02.2026

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG...

186. ESMO Awards - Episode 6 25.01.2026

ESMO Episode 6 is here! The longest award ceremony in the world continues. This episode covers colorectal cancer, a cancer stream that has relied heavily on the same three drugs for the past twenty-five years. We cover the golden pinnacle of real-world use cases for CTDNA, neoadjuvant immunotherapy in those with proficient MMR colorectal cancer, whether Zanzalimab helps in refractory colorectal ca...

185. ESMO Awards - Episode 5 21.01.2026

We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers. This episode covers FGFR inhibitors (Bemartizumab), updates on the MATTERHORN trial, the use of immunotherapy with trastuzu...

184. ESMO Awards - Episode 4 13.12.2025

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies. Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immun...

183. ESMO Awards - Episode 3 05.12.2025

For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer. Studies: DeLLphi-303 SOHO-01 ALBATROS PAULIEN DREAM3R OptiTROP-Lung04 For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at...

182. ESMO Awards - Episode 2 26.11.2025

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world. Studies: SOLTI-RIBOLARIS POSITIVE monarchE: DESTINY-Breast11 evERA ASCENT-03 TROPION-Breast02 trial ROSELLA DICE trial ENGOT-ov65/KEYNOTE-B96 study ROSELLA For more episodes, resources and blog pos...

182. ESMO Awards - Episode 1 15.11.2025

After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmi...

181. Back to Basics - Limited Stage Small Cell Lung Cancer 18.10.2025

In this episode, the focus shifts away from the more "garden-variety" non-small cell lung cancer and to its less common, frequently more aggressive sibling, small cell lung cancer. Here, Josh and Michael examine the management of limited-stage small cell lung cancer, which while accounting for a minority of cases, is no less interesting and potentially confusing. Studies discussed in this episode:...

180. Back to Basics - Metastatic NSCLC feat. KRAS and MET mutations 12.10.2025

On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation meets one of the least common in this battle of therapeutic tenacity. Studies discussed in this episode: INSIGHT-2 KRYSTAL-12 For more episodes, resources and blog posts, visit www.inq...

179. Back to Basics - Metastatic NSCLC feat. EGFR and ALK Driver Mutations 05.10.2025

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? You'll just have to listen and find out. Studies discussed in this episode: MARIPOSA CROWN For more episodes, resources...

178. Back to Basics - Metastatic Non Small Cell Lung Cancer (mNSCLCa) 27.09.2025

Advanced or Metastatic Non Small Cell Lung Cancer (mNSCLCa), is one of the most common causes of death worldwide. This week, Michael provides an excellent background on this type of cancer, and Josh provides an eloquently short introduction (for once). These trials look specifically at lung cancers without mutations, thus relying on immunotherapy and chemotherapy. As a side note, can you believe K...

177. Back to Basics - Early Non Small Cell Lung Cancer 13.09.2025

To Josh's immense displeasure, our series on genitourinary cancer is done. For now, at least. In this episode, Michael and Josh step into the heavy shadow of non-small cell lung cancer, the most common cause of cancer death in Australia. However, there is hope and new developments in the early-disease space that could significantly improve outcomes. Studies discussed in this episode Checkmate 816...

176. Back to Basics - Germ Cell Tumours (part 2) 06.09.2025

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately there are cases where more intense therapy is required. Listen on to find out about what to do when first line therapy is not enough! Studies discussed in this episode BEP - Williams...

175. Back to Basics - Germ Cell Tumours (part 1) 30.08.2025

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume multi-disciplinary centre to treat adequately. Or, you could just listen to Oncology for the Inquisitive Mind and be a pro in no time! Studies discussed in this episode EORTC-30982 de Wit et al (2001) Fo...

174. Back to Basics - Non Clear-Cell Renal Cell Cancer (RCC) 24.08.2025

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less common cluster of siblings to the much better established clear cell RCC. Treatment is on very similar patterns, so their studies today involve a lot of immunotherapy with a smattering of tyrosine kinase in...

173. NECTA (New South Wales Early Phase Clinical Trials Alliance) - The Origin Story 17.08.2025

How do you increase access to phase 1 trials for a state with a population of 8 million people spread across 800,000 km^2? You collaborate! In this context, we explore NECTA. The New South Wales Early Phase Clinical Trials Alliance (NECTA) plays a key role in speeding up the translation of cutting-edge medical research into real-world treatments, providing vital benefits to patients and the broade...

Listen to the Oncology for the Inquisitive Mind podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.